PMID- 35754320
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220716
IS  - 1743-2928 (Electronic)
IS  - 1351-0002 (Print)
IS  - 1351-0002 (Linking)
VI  - 27
IP  - 1
DP  - 2022 Dec
TI  - Therapeutic effects of sulforaphane in ulcerative colitis: effect on antioxidant 
      activity, mitochondrial biogenesis and DNA polymerization.
PG  - 128-138
LID - 10.1080/13510002.2022.2092378 [doi]
AB  - OBJECTIVES: Ulcerative colitis (UC), an inflammatory bowel disease, affects 
      mucosal lining of colon leading to inflammation and ulcers. Sulforaphane is a 
      natural compound obtained from cruciferous vegetables. We aimed to investigate 
      potential therapeutic effects of sulforaphane in experimentally induced UC in 
      rats through affection antioxidant activity, mitochondrial biogenesis and DNA 
      polymerization. METHODS: UC was induced in rats via an intracolonic single 
      administration of 2 ml of 4% acetic acid. UC rats were treated with 15 mg/kg 
      sulforaphane. Samples of colon were used to investigate gene expression and 
      protein levels of peroxisome proliferator-activated receptor-gamma coactivator 
      (PGC-1), mitochondrial transcription factor A (TFAM), mammalian target of 
      rapamycin (mTOR), cyclin D1, nuclear factor erythroid 2-related factor-2 (Nrf2), 
      heme Oxygenase-1 (HO-1) and proliferating cell nuclear antigen (PCNA). RESULTS: 
      UC showed dark distorted Goblet cell nucleus with disarranged mucus granules and 
      no distinct brush border with atypical microvilli. All morphological changes were 
      improved by treating with sulforaphane. Finally, treatment with sulforaphane 
      significantly increased expression of PGC-1, TFAM, Nrf2 and HO-1 associated with 
      reduction in expression of mTOR, cyclin D1 and PCNA. CONCLUSION: Sulforaphane 
      could cure UC in rats. The protective activity can be explained by enhancing 
      antioxidant activity, elevating mitochondrial biogenesis and inhibiting DNA 
      polymerization.
FAU - Alattar, Abdullah
AU  - Alattar A
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of 
      Tabuk, Tabuk, Saudi Arabia.
FAU - Alshaman, Reem
AU  - Alshaman R
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of 
      Tabuk, Tabuk, Saudi Arabia.
FAU - Al-Gayyar, Mohammed M H
AU  - Al-Gayyar MMH
AUID- ORCID: 0000-0003-4777-3919
AD  - Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 
      Egypt.
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, 
      Tabuk, Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Redox Rep
JT  - Redox report : communications in free radical research
JID - 9511366
RN  - 0 (Antioxidants)
RN  - 0 (Isothiocyanates)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Sulfoxides)
RN  - 136601-57-5 (Cyclin D1)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - GA49J4310U (sulforaphane)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - *Colitis, Ulcerative/chemically induced/drug therapy/metabolism
MH  - Cyclin D1
MH  - DNA
MH  - Isothiocyanates
MH  - Mammals/genetics/metabolism
MH  - *NF-E2-Related Factor 2/metabolism
MH  - Organelle Biogenesis
MH  - Polymerization
MH  - Proliferating Cell Nuclear Antigen
MH  - Rats
MH  - Sulfoxides
MH  - TOR Serine-Threonine Kinases
PMC - PMC9246005
OTO - NOTNLM
OT  - Cyclin D1
OT  - heme oxygenase-1 (HO-1)
OT  - mammalian target of rapamycin (mTOR)
OT  - mitochondrial transcription factor A (TFAM)
OT  - nuclear factor erythroid 2-related factor 2 (Nrf2)
OT  - peroxisome proliferator-activated receptor-gamma coactivator (PGC-1)
OT  - proliferating cell nuclear antigen (PCNA)
OT  - ulcerative colitis
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/06/28 06:00
MHDA- 2022/06/29 06:00
PMCR- 2022/06/26
CRDT- 2022/06/27 03:03
PHST- 2022/06/27 03:03 [entrez]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2022/06/26 00:00 [pmc-release]
AID - 2092378 [pii]
AID - 10.1080/13510002.2022.2092378 [doi]
PST - ppublish
SO  - Redox Rep. 2022 Dec;27(1):128-138. doi: 10.1080/13510002.2022.2092378.